PolyPid Correlations
| PYPD Stock | USD 2.96 0.11 3.58% |
The current 90-days correlation between PolyPid and Cue Biopharma is 0.04 (i.e., Significant diversification). The correlation of PolyPid is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
PolyPid Correlation With Market
Average diversification
The correlation between PolyPid and DJI is 0.15 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding PolyPid and DJI in the same portfolio, assuming nothing else is changed.
PolyPid |
Moving against PolyPid Stock
| 0.31 | DNTH | Dianthus Therapeutics Earnings Call Today | PairCorr |
| 0.45 | VRTX | Vertex Pharmaceuticals | PairCorr |
| 0.33 | CDTTW | Conduit Pharmaceuticals | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between PolyPid Stock performing well and PolyPid Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze PolyPid's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CUE | 4.90 | 0.01 | 0.00 | (0.08) | 0.00 | 8.51 | 38.78 | |||
| ANIX | 3.38 | 0.23 | 0.05 | 0.09 | 3.74 | 7.14 | 26.44 | |||
| INMB | 4.63 | 0.78 | 0.16 | 1.01 | 4.50 | 12.57 | 28.67 | |||
| INAB | 4.99 | (0.32) | 0.00 | (0.52) | 0.00 | 11.54 | 32.12 | |||
| EFTR | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| LABP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| APGN | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| NAVB | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| ANGN | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| ANEB | 5.11 | 0.40 | 0.06 | 0.18 | 5.31 | 19.58 | 40.87 |
PolyPid Corporate Management
| Ori Warshavsky | Chief US | Profile | |
| Dikla Akselbrad | Chief Officer | Profile | |
| Malka Reichart | Scientific Director | Profile | |
| Rivi Levari | Vice Resource | Profile | |
| Orna Blum | Legal Counsel | Profile | |
| JeanMarc PharmD | Chief Officer | Profile | |
| Tal Vilnai | General Secretary | Profile |